Psych CASC / OSCE · General adult psychiatry — bipolar and related disorders
Explain bipolar I diagnosis and lithium plan — CASC communication station
MRCPsych/FRANZCP-style communication station: explain bipolar I after first mania, lithium initiation and monitoring, BALANCE maintenance rationale, sleep and early-warning signs, and antidepressant caution.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes active time after reading. You are the psychiatry registrar on the inpatient ward preparing for discharge planning. [4]
Candidate instructions. Explain bipolar I disorder after a first manic episode, the rationale for lithium maintenance, baseline and ongoing blood tests, common side-effects and toxicity warning signs, why sleep and early-warning signs matter, and why antidepressant monotherapy is not appropriate if depression returns. Check understanding and invite questions from patient and partner. [4]
Candidate scenario
He is now nearly euthymic after acute treatment with olanzapine and is ready for step-down. You plan lithium carbonate initiation with education, 12-hour trough monitoring (maintenance commonly toward 0.6–0.8 mmol/L, individualised), and at least 6–12 months of maintenance after a first mania, longer if residual risk. He fears “personality change” and “kidney failure for sure.” Partner asks about suicide risk. [1][3][4]
Marking domains
- Empathy, structure, agenda-setting with patient and partner
- Accurate plain-language explanation of bipolar I (lifetime mania gate)
- Clear lithium plan: why, dose concept, trough timing, monitoring schedule
- Toxicity red flags and interacting drugs (NSAIDs, dehydration)
- Balanced suicide discussion including lithium evidence without false guarantees
- Antidepressant caution for future depression
- Sleep/early-warning-sign plan and teach-back [4]
Reveal assessor key
Open and agenda-set. Name time available; ask main worries (kidneys, personality, work, suicide). Include partner with consent. [4]
Explain diagnosis. “Bipolar I means you have had a manic episode — a period of pathologically high energy and mood with little need for sleep and risky decisions lasting days and disrupting life. You do not need depression to have the diagnosis, but depression can occur later. It is a medical illness, not a character flaw, and it is treatable.” [4]
Explain lithium. Lithium is one of the best-evidenced long-term treatments to prevent another mania or depression; trial evidence (BALANCE) supports lithium over valproate alone for relapse prevention in bipolar I when tolerated. We check kidney, thyroid, calcium, and sometimes ECG before and during treatment. Levels are timed 12 hours after the dose. Common effects include tremor, thirst, weight change; dangerous toxicity includes severe tremor, vomiting, confusion, unsteadiness — seek urgent help and hold doses. Avoid new NSAIDs and stay hydrated; tell other doctors you take lithium.[1][3]
Suicide. Bipolar illness raises suicide risk, especially in mixed or depressive periods. Lithium is associated with reduced suicidal behaviour in evidence reviews — still, any suicidal thoughts need same-day contact. Crisis plan and means safety. [2]
Future depression. We would not start an antidepressant alone; options include adjusting lithium or using other polarity-safe medicines. Sleep is a vital sign — protect regular sleep and watch early warning signs (needing less sleep with more energy). [4]
Close. Summarise, teach-back, written information, clinic/lab appointments, crisis contacts. [4]
References
- [1]BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
- [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [3]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
- [4]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391